UNSPSC 51101686: Sulfaclozine or sulfachlorpyridazine

This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69YP7Z48CW. European Medicines Agency schedules Sulfaclozine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10693MIG. Sulfaclozine generally arises in the molecular formula C10H9CLN4O2S.

The term SULFACLOZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 25, no. 10 1971, list 11.) SULFACLOZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfaclozine or sulfachlorpyridazine bears US NLM identifiers UMLS ID C0038672 and NCI Concept Code C76974. SMILES: C1=CC(=CC=C1N)S(=O)(=O)NC2=CN=CC(=N2)CL.

UNSPSC 51101686 Sulfaclozine or sulfachlorpyridazine, a Commodity code, nominally covers specific pharmaceutical active ingredients, but recent state and local procurement activity under this code shows minimal alignment with the stated scope. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium in August 2026 for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) rather than sulfaclozine or sulfachlorpyridazine; Seminole County, Florida posted an IFB in June 2026 for Naloxone and drug deactivation systems, which are emergency medical and harm-reduction products unrelated to the code's nominal pharmaceutical ingredient scope. Neither recent opportunity reflects actual procurement of the active ingredient named in the code.

The issuing bodies in the recent sample are a state health department (Illinois) and a county government (Florida), both procuring through competitive bidding vehicles. Geographic activity centers on Illinois and Florida based on these two records. The code shows little relevant recent activity aligned with its stated scope; state and local procurement offices appear to be tagging broader pharmaceutical and medical-supply acquisitions under this Commodity code rather than sourcing the specific active ingredient it names. Firms pursuing this code should verify whether the mismatch reflects a data-classification artifact or a genuine shift in how jurisdictions are deploying the code in their procurement systems.